Genmab | GEN - Equity Capital And Reserves


Genmab reported DKK5.96B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 979.34M 46.68M Sep/2026
Almirall EUR 1.53B 43.26M Jun/2026
Amarin USD 444.41M 796K Sep/2026
Amgen USD 14.35B 2.66B Sep/2026
argenx SE USD 8.42B 1.09B Jun/2026
AstraZeneca USD 51.73B 1.43B Sep/2026
Bayer EUR 29.18B 533M Sep/2026
BioMarin Pharmaceutical USD 6.26B 65.66M Sep/2026
Demant DKK 11.24B 1.4B Jun/2026
Exelixis USD 1.83B 9.93M Sep/2026
Fresenius Medical Care EUR 13.76B 226.23M Sep/2026
Genmab DKK 5.96B 275M Jun/2026
GlaxoSmithKline GBP 18.75B 1.11B Sep/2026
GN Store Nord DKK 10.51B 241M Sep/2026
GRIFOLS EUR 5.79B 2.19B Sep/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Insmed USD 726.21M 31.28M Sep/2026
Lakefront Biotherapeutics EUR 3.26B 10.26M Jun/2026
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 30.17B 430M Jun/2026
Novartis USD 37.23B 4.72B Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 72.88B 3.31B Sep/2026
UCB EUR 10.87B 1.18B Dec/2025